ArticleTheranostics2019
Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 112 citations in OpenAlex.
- Synthetic and mechanistic outlines of magnetoelectric nanomedicine for targeted cancer therapy.Medical oncology (Northwood, London, England) · 2026Review
- Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer.Pharmaceutics · 2026Review
- Co-delivery of cisplatin and Bmi1 siRNA via nanocapsules overcomes chemoresistance in ovarian cancer.Scientific reports · 2026Article
- Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms.Cancers · 2025Review
- Designing the Next Generation of Biomaterials through Nanoengineering.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Applications of Nanoparticles in the Diagnosis and Treatment of Ovarian Cancer.Nanomaterials (Basel, Switzerland) · 2025Review
- Construction of prognostic scoring model for ovarian cancer based on deep learning algorithm.Discover oncology · 2025Article
- Iron oxide based magnetic nanoparticles for hyperthermia, MRI and drug delivery applications: a review.RSC advances · 2025Review
- Iron oxide nanoparticles: a versatile nanoplatform for the treatment and diagnosis of ovarian cancer.Therapeutic delivery · 2025Review
- Nanotechnology-based drug delivery system for the diagnosis and treatment of ovarian cancer.Discover oncology · 2025Review
- Carbon Nanotubes in the Diagnosis and Treatment of Ovarian Cancer.Indian journal of microbiology · 2025Article
- Developing the Strategy to Use Silk Spheres for Efficient, Targeted Delivery of Oligonucleotide Therapeutics to Cancer Cells.International journal of nanomedicine · 2025Article
- Fluorescence molecular imaging technology: a promising new strategy for the diagnosis and treatment of gynecologic tumors.Frontiers in bioengineering and biotechnology · 2025Review
- Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.International journal of molecular sciences · 2024Review
- Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Potential role of lncRNA LOXL1-AS1 in human cancer development: a narrative review.Translational cancer research · 2024Review
- Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems.International journal of nanomedicine · 2024Review
- Hybrid Magnetic Lipid-Based Nanoparticles for Cancer Therapy.Pharmaceutics · 2023Review
- New trends in diagnosing and treating ovarian cancer using nanotechnology.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Minati SatpathyDepartments of Surgery, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Liya WangDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Rafal J ZielinskiDepartment of Experimental Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA.
Weiping QianDepartments of Surgery, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Y Andrew WangOcean NanoTech, LLC, San Diego, CA, 92126, USA.
Aaron M MohsDepartment of Biomedical Engineering, Emory University, Atlanta, GA, 30322, USA.
Brad A KairdolfDepartment of Biomedical Engineering, Emory University, Atlanta, GA, 30322, USA.
Xin JiOcean NanoTech, LLC, San Diego, CA, 92126, USA.
Jacek CapalaClinical Radiation Oncology Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Malgorzata LipowskaDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Shuming NieDepartment of Biomedical Engineering, Emory University, Atlanta, GA, 30322, USA.
Hui MaoDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Lily YangDepartments of Surgery, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Emory University · USOcean NanoTech (United States) · USThe University of Texas MD Anderson Cancer Center · US
Funding
Contrast-Enhanced and Image-Guided Surgery of Lung CancerR01CA163256 · NCI · EMORY UNIVERSITY · PI JO, HANJOONG, SINGHAL, SUNIL · 2011 to 2015
$6.5MStroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer TherapyU01CA198913 · NCI · EMORY UNIVERSITY · PI MAO, HUI, YANG, LILY · 2015 to 2019
$3.0MTargeted therapy of peritoneal carcinomatosis using theranostic nanoparticlesR01CA202846 · NCI · EMORY UNIVERSITY · PI MAO, HUI, WANG, YONGQIANG ANDREW · 2016 to 2020
$2.4MTheranostic Nano particles for Targeted Treatment of Pancreatic CancerU01CA151810 · NCI · EMORY UNIVERSITY · PI MAO, HUI, YANG, LILY · 2010 to 2014
$2.2MMRI Capable Receptor Targeted Drug Delivery for Pancreatic CancerR01CA154846 · NCI · EMORY UNIVERSITY · PI MAO, HUI, YANG, LILY · 2011 to 2015
$2.1MTargeted Therapy of Triple Negative Breast Cancer Using Theranostic NanoparticlesR01CA154129 · NCI · EMORY UNIVERSITY · PI YANG, LILY · 2011 to 2015
$1.7MTargeted Nanoprobes For Intraoperative optical Imaging of Breast Cancer MarginsR01CA133722 · NCI · EMORY UNIVERSITY · PI YANG, LILY · 2008 to 2012
$1.6MNCI NIH HHS R01 CA133722NCI NIH HHS R01 CA154129NCI NIH HHS R01 CA154846NCI NIH HHS R01 CA163256NCI NIH HHS R01 CA202846NCI NIH HHS U01 CA151810NCI NIH HHS U01 CA198913
Abstract
Cancer heterogeneity and drug resistance limit the efficacy of cancer therapy. To address this issue, we have developed an integrated treatment protocol for effective treatment of heterogeneous ovarian cancer.
Indexed as
Drug Delivery SystemsMagnetic Resonance Imaging, InterventionalAnimalsAntineoplastic AgentsCell Line, TumorCisplatinErb-b2 Receptor Tyrosine KinasesFeasibility StudiesFemaleFerric CompoundsHumansMetal NanoparticlesMice, NudeOvarian NeoplasmsTheranostic NanomedicineXenograft Model Antitumor AssaysAntineoplastic AgentsCisplatinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFerric Compoundsferric oxideMR image-guided cancer therapyresistant mechanismspectroscopic imagingtargeted drug deliverytheranostic nanoparticles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.